Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 99.
4. lappuse
... antibiotic drugs 331 432 Packaging and labeling of antibiotic drugs 339 433 Exemptions from antibiotic certification and la- beling requirements 340 436 Tests and methods of assay of antibiotic and anti- biotic - containing drugs 351 ...
... antibiotic drugs 331 432 Packaging and labeling of antibiotic drugs 339 433 Exemptions from antibiotic certification and la- beling requirements 340 436 Tests and methods of assay of antibiotic and anti- biotic - containing drugs 351 ...
5. lappuse
... antibiotic drugs 968 460 Antibiotic drugs intended for use in laboratory di- agnosis of disease 1019 461-499 [ Reserved ] EDITORIAL NOTE : For nomenclature changes to chapter I see 59 FR 14366 , Mar. 28 , 1994 . 5 Food and Drug ...
... antibiotic drugs 968 460 Antibiotic drugs intended for use in laboratory di- agnosis of disease 1019 461-499 [ Reserved ] EDITORIAL NOTE : For nomenclature changes to chapter I see 59 FR 14366 , Mar. 28 , 1994 . 5 Food and Drug ...
7. lappuse
... antibiotic , and other regulatory provi- sions of the Federal Food , Drug , and Cosmetic Act regarding fixed combina- tion dosage form prescription drugs for humans is as follows : ( a ) Two or more drugs may be com- bined in a single ...
... antibiotic , and other regulatory provi- sions of the Federal Food , Drug , and Cosmetic Act regarding fixed combina- tion dosage form prescription drugs for humans is as follows : ( a ) Two or more drugs may be com- bined in a single ...
63. lappuse
... antibiotic drug product approved under part 314 or of a licensed biological product . ( e ) Guidance . FDA may , on its own initiative , issue guidance on the appli- cability of this part to particular in- vestigational uses of drugs ...
... antibiotic drug product approved under part 314 or of a licensed biological product . ( e ) Guidance . FDA may , on its own initiative , issue guidance on the appli- cability of this part to particular in- vestigational uses of drugs ...
95. lappuse
... antibiotic drug prod- uct shipped in accordance with the pro- visions of section 801 ( d ) of the act . ( 5 ) This paragraph does not apply to the export of new drugs ( including bio- logical products ) approved for export under section ...
... antibiotic drug prod- uct shipped in accordance with the pro- visions of section 801 ( d ) of the act . ( 5 ) This paragraph does not apply to the export of new drugs ( including bio- logical products ) approved for export under section ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning